The overall trial and subgroup answered different questions
Participants received S. cerevisiae CNCM I-3856 or placebo for 12 weeks. The main responder definition required a substantial pain/discomfort reduction during at least four of the last eight weeks. [1]
The probiotic did not improve the overall responder result. Planned analyses of participants with constipation-predominant IBS found symptom signals, which the authors said required confirmation. A subgroup finding does not turn the overall trial positive. [1]
The strain code does not mean ordinary baking yeast
This was a defined probiotic preparation, not a test of any product containing S. cerevisiae. The organism’s use in fermentation cannot establish equivalent clinical effects for another strain or preparation. [1]
The report disclosed public research support and Lesaffre-funded writing, with company employment and consultancy relationships. It also noted that an incorrect registry description of the outcome window was corrected after completion, while stating that the approved protocol itself had not changed. [1]
Preserve the hierarchy of findings
Imagine an overall trial is negative but one planned subgroup improves. Report both results, and treat the subgroup as a narrower finding needing confirmation rather than a universal benefit.
| Detail | Interpretation |
|---|---|
| Overall responder outcome | No demonstrated benefit |
| Constipation subgroup | Signal needing confirmation |
| CNCM I-3856 | Not a generic yeast substitute |
Sources for this article
- Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: improvement in abdominal pain and bloating in those with predominant constipation - PMC
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.